Rejection, approval & 2 moves to PhIII change Allergan conversation
This article was originally published in Scrip
Executive Summary
For the third time, the FDA has rejected Allergan's experimental inhaled migraine drug dihydroergotamine, which has now changed its moniker from Levadex to Semprana.